A Double-blind, Placebo-controlled, Phase 2a Proof-of-concept Trial of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19
Latest Information Update: 09 Dec 2022
At a glance
- Drugs Dalcetrapib (Primary)
- Indications SARS-CoV-2 acute respiratory disease
- Focus Proof of concept; Therapeutic Use
- Acronyms dal-COVID
- Sponsors DalCor Pharmaceuticals
- 01 Jun 2021 Status changed from active, no longer recruiting to completed.
- 22 Apr 2021 Status changed from recruiting to active, no longer recruiting.
- 15 Mar 2021 Planned End Date changed from 1 Mar 2021 to 1 May 2021.